Frequency of Tumor Lysis Syndrome Among Patients Diagnosed with Hematologic Malignancies
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-117154
Abstract: INTRODUCTION: The risk of tumor lysis syndrome (TLS) varies depending upon the underlying malignancy, tumor burden, and anti-tumor activity of the treatment administered. With the recent approval of several anti-cancer treatments across hematologic malignancies, mitigation… read more here.
Keywords: treatment; tls; equity ownership; hematologic malignancies ... See more keywords